<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045161</url>
  </required_header>
  <id_info>
    <org_study_id>LAS-MD-38</org_study_id>
    <nct_id>NCT01045161</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)</brief_title>
  <acronym>LAS-MD-38</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium
      bromide doses compared with placebo in the treatment of moderate to severe, stable chronic
      obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week run-in period
      followed by a 12-week double-blind, placebo-controlled treatment period. This will be
      followed by an open-label 40-week treatment period and a 2-week follow up phone call. All
      patients will receive the higher Aclidinium Bromide during the 40-week open label treatment
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Change from baseline (Week 0) to Week 12</time_frame>
    <description>Change from baseline in Trough forced expiratory volume in 1 second before the morning dose of aclidinium bromide, Last Observation Carried Forward (LOCF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Morning Predose (Trough) FEV1</measure>
    <time_frame>Change from baseline (Week 0) to 52 Weeks</time_frame>
    <description>Change from Baseline in Morning Pre-dose (trough) Forced Expiratory Volume in 1 Second (FEV1) at Week 52, Lost Observation Carried Forward (LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Peak Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Change from baseline (Week 0) to Week 12</time_frame>
    <description>Change from baseline in peak FEV1 at week 12, Last Observation Carried Forward (LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Peak FEV1</measure>
    <time_frame>Change from baseline (Week 0) to 52 Weeks</time_frame>
    <description>Change from Baseline in Peak FEV1 (L) at Week 52, Last Observation Carried Forward (LOCF)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">544</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide</intervention_name>
    <description>Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC
             &lt; 70%, and postbronchodilator FEV1 ≥ 30% and &lt; 80% predicted

          -  Current or former cigarette smokers

        Exclusion Criteria:

          -  Patients who have been hospitalized for an acute COPD exacerbation within 3 months
             before the first visit

          -  Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1

          -  Patient with any clinically significant respiratory conditions other than COPD,
             cardiovascular conditions or mental illness

          -  History or presence of asthma verified from medical records

          -  Chronic use of oxygen therapy greater than or equal to 15 hours per day

          -  Patient with uncontrolled infection due to HIV and/or active hepatitis

          -  Patients with a history of hypersensitivity reaction to inhaled anticholinergics

          -  Patients with clinically significant cardiovascular conditions, including myocardial
             infarction during the previous 6 months, newly diagnosed arrhythmia within the
             previous 3 months, unstable angina, unstable arrhythmia that had required changes in
             pharmacological therapy or other intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Forest Investigative Site 1493</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1419</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1413</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1353</name>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <zip>35128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1379</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2065</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1451</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1388</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1424</name>
      <address>
        <city>Rolling Hill Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1427</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1418</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2009</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1374</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1331</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1380</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1447</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1364</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1516</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1403</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1485</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1352</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1391</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1376</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1372</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1407</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1185</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1386</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1411</name>
      <address>
        <city>Calhoun</city>
        <state>Georgia</state>
        <zip>30701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1528</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0679</name>
      <address>
        <city>Coeur d' Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1385</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1409</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1479</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2022</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1441</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1149</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1406</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1080</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2033</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1090</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1430</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1446</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1360</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1412</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1518</name>
      <address>
        <city>North East</city>
        <state>Maryland</state>
        <zip>21901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1442</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1421</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1029</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1405</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0889</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1487</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1128</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>58435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1527</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1124</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1118</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1399</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1400</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1354</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1367</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1476</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1363</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1390</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1422</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1359</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1355</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1486</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1489</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <zip>10538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1425</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1373</name>
      <address>
        <city>North Syracuse</city>
        <state>New York</state>
        <zip>13212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1392</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1366</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1136</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1371</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1361</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1433</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1530</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1393</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1362</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2018</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 2043</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1377</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <zip>19426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1423</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1428</name>
      <address>
        <city>Feasterville</city>
        <state>Pennsylvania</state>
        <zip>19053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1443</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1510</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1449</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <zip>16684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1445</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1477</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1144</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1517</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1506</name>
      <address>
        <city>Grenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1450</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1526</name>
      <address>
        <city>Fayetteville</city>
        <state>Tennessee</state>
        <zip>37337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1356</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1417</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1389</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1440</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1494</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1375</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1444</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1401</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1381</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1357</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1426</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1410</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1480</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1402</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1404</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1358</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0988</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 1177</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 0969</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4070&amp;filename=las-md-38-synopsis.pdf</url>
    <description>las-md-38-synopsis</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>August 14, 2012</results_first_submitted>
  <results_first_submitted_qc>November 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2015</results_first_posted>
  <disposition_first_submitted>January 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 9, 2012</disposition_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Airflow Obstruction, Chronic</keyword>
  <keyword>Chronic Airflow Obstruction</keyword>
  <keyword>Chronic Obstructive Airway Disease</keyword>
  <keyword>Chronic Obstructive Lung Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment occurred from December of 2009 to June of 2010 at 112 study sites (110 in the United States and 2 additional sites in Canada).</recruitment_details>
      <pre_assignment_details>A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Of these patients, 405 had a baseline and postbaseline assessment for the ITT Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Part A Placebo to Aclidinium Bromide 400 μg - Part B</title>
          <description>Dose matched placebo, twice per day, oral inhalation for 12 weeks of double-blind treatment. After 12 weeks, patients who were on placebo received open-label Aclidinium Bromide, 400 microgram dose, for an additional 40 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Aclidinium Bromide 200μg to Aclidinium Bromide 400μg</title>
          <description>Aclidinium bromide 200 microgram dose, oral inhalation, twice per day for 12 weeks of double-blind treatment. After 12 weeks, patients who were Aclidinium bromide 200 microgram dose, received open-label Aclidinium Bromide, 400 microgram dose, for an additional 40 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Aclidinium Bromide 400μg to Aclidinium Bromide 400μg</title>
          <description>Aclidinium bromide, 400 microgram dose, oral inhalation twice per day for 12 weeks of double-blind treatment. After 12 weeks, patients continued to receive Aclidinium bromide, 400 microgram dose as an open-label treatment for an additional 40 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A - 12 Weeks Double Blind Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COPD Exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B - 40 Additional Weeks Open Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COPD Exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Baseline characteristics for Part B are based on participant totals of 147, 154 and 147</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Part A / Placebo to Aclidinium Bromide 400μg Part B</title>
          <description>Dose-matched placebo, twice per day, oral inhalation for 12 weeks of double-blind treatment in Part A of the Trial.
After week 12 (conclusion of Part A), patients who were on placebo received open-label Aclidinium Bromide, 400 microgram dose, for an additional 40 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Aclidinium Bromide(AB) 200μg Part A / AB 200μg to 400μg Part B</title>
          <description>Aclidinium bromide 200 microgram dose, oral inhalation, twice per day for 12 weeks of double-blind treatment in Part A of the Trial.
After week 12 (conclusion of Part A), patients who were on a double-blind, 200 microgram Aclidinium Bromide dose, were switched to open-label Aclidinium Bromide at a 400 microgram dose for an additional 40 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Aclidinium Bromide(AB) 400μg Part A / AB 400μg to 400μg Part B</title>
          <description>Aclidinium bromide, 400 microgram dose, oral inhalation twice per day for 12 weeks of double-blind treatment in Part A of the Trial.
After week 12 (conclusion of Part A), patients who were on a double-blind, 400 microgram Aclidinium Bromide dose, were switched to open-label Aclidinium Bromide at the same 400 microgram dose for an additional 40 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="182"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="177"/>
            <count group_id="B4" value="542"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="9.3"/>
                    <measurement group_id="B2" value="63.4" spread="8.5"/>
                    <measurement group_id="B3" value="63.2" spread="9.0"/>
                    <measurement group_id="B4" value="62.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.1"/>
                    <measurement group_id="B2" value="63.8" spread="8.2"/>
                    <measurement group_id="B3" value="63.1" spread="8.6"/>
                    <measurement group_id="B4" value="62.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥ 40 to &lt; 60 years - Part A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60 to &lt; 70 years - Part A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 70 years - Part A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 40 to &lt; 60 years - Part B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60 to &lt; 70 years - Part B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 70 years - Part B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Part A</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Part B</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Part A</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Part B</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change from baseline in Trough forced expiratory volume in 1 second before the morning dose of aclidinium bromide, Last Observation Carried Forward (LOCF)</description>
        <time_frame>Change from baseline (Week 0) to Week 12</time_frame>
        <population>Of 544 patients randomized, 542 patients received at least 1 dose of double-blind treatment and were included in the Safety Population. Of these patients, 541 had a baseline and at least 1 postbaseline FEV1 assessment and qualified for the Intent to Treat (ITT) Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dose-matched placebo twice per day, inhaled for 12 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 200 μg</title>
            <description>Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium Bromide 400 μg</title>
            <description>Inhaled Aclidinium bromide 400 μg twice per day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change from baseline in Trough forced expiratory volume in 1 second before the morning dose of aclidinium bromide, Last Observation Carried Forward (LOCF)</description>
          <population>Of 544 patients randomized, 542 patients received at least 1 dose of double-blind treatment and were included in the Safety Population. Of these patients, 541 had a baseline and at least 1 postbaseline FEV1 assessment and qualified for the Intent to Treat (ITT) Population.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.015"/>
                    <measurement group_id="O2" value="0.043" spread="0.015"/>
                    <measurement group_id="O3" value="0.064" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Peak Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change from baseline in peak FEV1 at week 12, Last Observation Carried Forward (LOCF)</description>
        <time_frame>Change from baseline (Week 0) to Week 12</time_frame>
        <population>Of 544 patients randomized, 542 patients received at least 1 dose of double-blind treatment and were included in the Safety Population. Of these patients, 541 had a baseline and at least 1 postbaseline FEV1 assessment and qualified for the Intent to Treat (ITT) Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dose-matched placebo twice per day, inhaled for 12 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 200 μg</title>
            <description>Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium Bromide 400 μg</title>
            <description>Inhaled Aclidinium bromide 400 μg twice per day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Peak Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change from baseline in peak FEV1 at week 12, Last Observation Carried Forward (LOCF)</description>
          <population>Of 544 patients randomized, 542 patients received at least 1 dose of double-blind treatment and were included in the Safety Population. Of these patients, 541 had a baseline and at least 1 postbaseline FEV1 assessment and qualified for the Intent to Treat (ITT) Population.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" spread="0.018"/>
                    <measurement group_id="O2" value="0.202" spread="0.018"/>
                    <measurement group_id="O3" value="0.212" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Morning Predose (Trough) FEV1</title>
        <description>Change from Baseline in Morning Pre-dose (trough) Forced Expiratory Volume in 1 Second (FEV1) at Week 52, Lost Observation Carried Forward (LOCF)</description>
        <time_frame>Change from baseline (Week 0) to 52 Weeks</time_frame>
        <population>A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Of these patients, 405 had a baseline and postbaseline assessment for the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Aclidinium Bromide 400 μg</title>
            <description>Dose matched placebo, oral inhalation, twice per day for 12 weeks of treatment. At week 12, patients who were on placebo were switched to open label 400µg aclidinium bromide for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 200 μg - Aclidinium Bromide 400 μg</title>
            <description>Aclidinium bromide, 200 μg dose, oral inhalation, twice per day for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg were switched to open label 400µg aclidinium bromide for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium Bromide 400 μg - Aclidinium Bromide 400 μg</title>
            <description>Aclidinium bromide, 400 μg dose, oral inhalation, twice per day for 12 weeks of treatment. At week 12, patients received open label 400µg aclidinium bromide for 40 additional weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Morning Predose (Trough) FEV1</title>
          <description>Change from Baseline in Morning Pre-dose (trough) Forced Expiratory Volume in 1 Second (FEV1) at Week 52, Lost Observation Carried Forward (LOCF)</description>
          <population>A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Of these patients, 405 had a baseline and postbaseline assessment for the ITT Population.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="0.021"/>
                    <measurement group_id="O2" value="0.029" spread="0.020"/>
                    <measurement group_id="O3" value="0.048" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0192</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean difference</param_type>
            <param_value>0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Peak FEV1</title>
        <description>Change from Baseline in Peak FEV1 (L) at Week 52, Last Observation Carried Forward (LOCF)</description>
        <time_frame>Change from baseline (Week 0) to 52 Weeks</time_frame>
        <population>A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Of these patients, 405 had a baseline and postbaseline assessment for the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Aclidinium Bromide 400 μg</title>
            <description>Dose matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo switched to open label 400µg aclidinium bromide for 40 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 200 μg - Aclidinium Bromide 400 μg</title>
            <description>Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg switched to open label 400µg aclidinium bromide for 40 weeks</description>
          </group>
          <group group_id="O3">
            <title>Aclidinium Bromide 400 μg - Aclidinium Bromide 400 μg</title>
            <description>Aclidinium bromide 400 μg dose, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg switched to open label 400µg aclidinium bromide for 40 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Peak FEV1</title>
          <description>Change from Baseline in Peak FEV1 (L) at Week 52, Last Observation Carried Forward (LOCF)</description>
          <population>A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Of these patients, 405 had a baseline and postbaseline assessment for the ITT Population.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="0.023"/>
                    <measurement group_id="O2" value="0.176" spread="0.023"/>
                    <measurement group_id="O3" value="0.172" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event reporting began in December of 2009 and concluded in July of 2011 at 112 study sites (110 in the United States and 2 additional sites in Canada).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Part A</title>
          <description>Dose matched placebo, twice per day, oral inhalation for 12 weeks of double-blind treatment.</description>
        </group>
        <group group_id="E2">
          <title>Aclidinium Bromide 200 μg - Part A</title>
          <description>Aclidinium bromide 200 microgram dose, oral inhalation, twice per day for 12 weeks of double-blind treatment.</description>
        </group>
        <group group_id="E3">
          <title>Aclidinium Bromide 400 μg - Part A</title>
          <description>Aclidinium bromide, 400 microgram dose, oral inhalation twice per day for 12 weeks of double-blind treatment.</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Aclidinium Bromide 400 μg - Part B</title>
          <description>After week 12 (conclusion of Part A), patients who were on placebo received open-label Aclidinium Bromide, 400 microgram dose, for an additional 40 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Aclidinium Bromide 200μg to Aclidinium Bromide 400μg - Part B</title>
          <description>Part B - After week 12 (conclusion of Part A), patients who were on a double-blind, 200 microgram Aclidinium Bromide dose, were switched to open-label Aclidinium Bromide at a 400 microgram dose for an additional 40 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Aclidinium Bromide 400μg to Aclidinium Bromide 400μg - Part B</title>
          <description>After week 12 (conclusion of Part A), patients who were on a double-blind, 400 microgram Aclidinium Bromide dose, were switched to open-label Aclidinium Bromide at the same 400 microgram dose for an additional 40 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Gastrenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Agitated depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study.
Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical</name_or_title>
      <organization>Study Information Center</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

